Literature DB >> 6423326

Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy.

R B Narayanan, S Laal, A K Sharma, L K Bhutani, I Nath.   

Abstract

The nature and histological pattern of the cutaneous infiltrates of 17 leprosy patients in reversal reactions (Type I) and erythema nodosum leprosum (Type II, ENL) were compared with tissues from 18 non-reactional borderline leprosy (BT, BL) and lepromatous leprosy (LL) patients using monoclonal antibodies and immunofluorescence. Reactional BT lesions showed a mild increase in OKT11+ pan T cells as compared to non-reactional tissues and a significant influx of OKT8+ (suppressor/cytotoxic) cells which were peripherally localized in the lymphocyte mantle surrounding the epithelioid cells. The Leu 3a+ (helper/inducer) cells were scattered amongst the lymphocytes and macrophages. The mean ratio (+/- s.d.) of Leu 3a+/OKT8+ cells was 1.88 +/- 0.64 in Type I BT reactions as compared to 2.95 +/- 0.95 in BT lesions. In contrast, lesions of BL reversal reactions and ENL showed a more marked increase in pan T cells with a preponderance of the helper/inducer subset, Leu 3a+/OKT8+ ratio being 2.26 +/- 0.61 and 0.93 +/- 0.57 in BL reactional and non-reactional lesions, respectively. Interestingly, this increase in the numbers of the T cells reached levels observed in BT lesions. The distribution pattern of OKT8+ cells was similar to Leu 3a+, both being diffusely scattered amongst the bacilli laden macrophages. Ia like antigens were present in all granulomas and were abundant on lymphocytes and macrophages and less conspicuous on epithelioid cells. T6+ Langerhans cells were uniformly increased in all reactional lesions. It would appear that the changes observed in both Type I and Type II reactions are similar in the lepromatous group of patients. They differ significantly from the BT reversal reaction in terms of the dominant T cell subset and the microanatomical distribution of the OKT8+ cells in the lesions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6423326      PMCID: PMC1535912     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  6 in total

1.  Immune complexes and complement hypercatabolism in patients with leprosy.

Authors:  B Bjorvatn; R S Barnetson; G Kronvall; R H Zubler; P H Lambert
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

2.  Erythema nodosum leprosum: a clinical manifestation of the arthus phenomenon.

Authors:  S N Wemambu; J L Turk; M F Waters; R J Rees
Journal:  Lancet       Date:  1969-11-01       Impact factor: 79.321

Review 3.  Immunological phenomena in leprosy and related diseases.

Authors:  J L Turk; A D Bryceson
Journal:  Adv Immunol       Date:  1971       Impact factor: 3.543

4.  Classification of leprosy according to immunity. A five-group system.

Authors:  D S Ridley; W H Jopling
Journal:  Int J Lepr Other Mycobact Dis       Date:  1966 Jul-Sep

5.  In situ demonstration of T lymphocyte subsets in granulomatous inflammation: leprosy, rhinoscleroma and sarcoidosis.

Authors:  R L Modlin; F M Hofman; P R Meyer; O P Sharma; C R Taylor; T H Rea
Journal:  Clin Exp Immunol       Date:  1983-03       Impact factor: 4.330

6.  T cell subsets in leprosy lesions: in situ characterization using monoclonal antibodies.

Authors:  R B Narayanan; L K Bhutani; A K Sharma; I Nath
Journal:  Clin Exp Immunol       Date:  1983-03       Impact factor: 4.330

  6 in total
  18 in total

Review 1.  T cell and cytokine patterns in leprosy skin lesions.

Authors:  P A Sieling; R L Modlin
Journal:  Springer Semin Immunopathol       Date:  1992

2.  Epidermal keratinocyte Ia expression, Langerhans cell hyperplasia and lymphocytic infiltration in skin lesions of leprosy.

Authors:  T H Rea; J Y Shen; R L Modlin
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

3.  Lepromatous leprosy patients show T helper 1-like cytokine profile with differential expression of interleukin-10 during type 1 and 2 reactions.

Authors:  P Sreenivasan; R S Misra; D Wilfred; I Nath
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

4.  The cellular composition of granulomas in mesenteric lymph nodes from patients with Crohn's disease.

Authors:  K Geboes; J van den Oord; C De Wolf-Peeters; V Desmet; P Rutgeerts; J Janssens; G Vantrappen; F Penninckx; R Kerremans
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

Review 5.  Immunopathology of leprosy granulomas.

Authors:  R L Modlin; T H Rea
Journal:  Springer Semin Immunopathol       Date:  1988

6.  Serum lymphocytotoxic activity in leprosy.

Authors:  F N Rasheed; M Locniskar; D J McCloskey; R S Hasan; T J Chiang; P Rose; R de Soldenhoff; H Festenstein; K P McAdam
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

7.  Natural emergence of antigen-reactive T cells in lepromatous leprosy patients during erythema nodosum leprosum.

Authors:  S Laal; L K Bhutani; I Nath
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

8.  Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment.

Authors:  D Little; S Khanolkar-Young; A Coulthart; S Suneetha; D N Lockwood
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

9.  Lepromatous leprosy with erythema nodosum leprosum as immune reconstitution inflammatory syndrome in an HIV-1 infected patient after initiation of antiretroviral therapy.

Authors:  Alexia Cusini; Huldrych F Günthard; Rainer Weber; Milo Huber; Jivko Kamarashev; Barbara Bertisch; Silke Peter; Bernhard Beck
Journal:  BMJ Case Rep       Date:  2009-12-01

10.  Accessory cell heterogeneity in lepromatous leprosy; dendritic cells and not monocytes support T cell responses.

Authors:  A Mittal; R S Mishra; I Nath
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.